BMO Capital Markets reaffirmed their outperform rating on shares of Gilead Sciences, Inc. (NASDAQ:GILD) in a research note published on Thursday morning. They currently have a $82.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $72.00.

Several other equities analysts have also weighed in on GILD. Vetr raised shares of Gilead Sciences from a buy rating to a strong-buy rating and set a $75.07 price objective on the stock in a research report on Tuesday, April 4th. J P Morgan Chase & Co reaffirmed an overweight rating and set a $82.00 price target on shares of Gilead Sciences in a research report on Thursday, April 6th. Jefferies Group LLC reaffirmed a buy rating and set a $82.00 price target on shares of Gilead Sciences in a research report on Thursday, April 6th. Zacks Investment Research raised shares of Gilead Sciences from a strong sell rating to a hold rating in a research report on Tuesday, April 11th. Finally, Cowen and Company reaffirmed a buy rating and set a $100.00 price target on shares of Gilead Sciences in a research report on Monday, April 17th. Twelve research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $80.31.

Gilead Sciences (NASDAQ GILD) traded up 0.20% on Thursday, hitting $76.09. 7,872,647 shares of the stock traded hands. The stock has a market cap of $99.37 billion, a price-to-earnings ratio of 8.26 and a beta of 1.20. Gilead Sciences has a 52 week low of $63.76 and a 52 week high of $82.10. The firm’s 50 day moving average is $69.98 and its 200 day moving average is $68.63.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.45. The company had revenue of $7.14 billion for the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company’s revenue was down 8.2% on a year-over-year basis. During the same period in the prior year, the firm earned $3.08 earnings per share. Equities analysts anticipate that Gilead Sciences will post $8.72 earnings per share for the current year.

WARNING: This piece was posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.watchlistnews.com/gilead-sciences-inc-gild-earns-outperform-rating-from-bmo-capital-markets/1464537.html.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be paid a dividend of $0.52 per share. The ex-dividend date is Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.74%. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.

In other Gilead Sciences news, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $71.06, for a total transaction of $355,300.00. Following the completion of the sale, the executive vice president now owns 102,988 shares in the company, valued at approximately $7,318,327.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gregg H. Alton sold 40,000 shares of the business’s stock in a transaction on Friday, July 21st. The shares were sold at an average price of $74.00, for a total transaction of $2,960,000.00. Following the sale, the executive vice president now owns 137,488 shares of the company’s stock, valued at approximately $10,174,112. The disclosure for this sale can be found here. Insiders have sold a total of 128,276 shares of company stock valued at $9,190,610 in the last 90 days. 1.30% of the stock is currently owned by company insiders.

Hedge funds have recently made changes to their positions in the stock. Silvercrest Asset Management Group LLC increased its position in Gilead Sciences by 0.5% in the fourth quarter. Silvercrest Asset Management Group LLC now owns 48,000 shares of the biopharmaceutical company’s stock worth $3,437,000 after buying an additional 255 shares in the last quarter. Girard Securities Inc. increased its position in Gilead Sciences by 3.4% in the fourth quarter. Girard Securities Inc. now owns 5,952 shares of the biopharmaceutical company’s stock worth $426,000 after buying an additional 197 shares in the last quarter. Franklin Resources Inc. increased its position in Gilead Sciences by 2.2% in the fourth quarter. Franklin Resources Inc. now owns 14,317,385 shares of the biopharmaceutical company’s stock worth $1,025,373,000 after buying an additional 313,703 shares in the last quarter. Intellectus Partners LLC purchased a new position in Gilead Sciences during the fourth quarter worth about $1,112,000. Finally, Moloney Securities Asset Management LLC purchased a new position in Gilead Sciences during the fourth quarter worth about $457,000. Institutional investors and hedge funds own 73.99% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.